Evidence map›Paper›PMID 36648883›Full record

ArticleHematology reports2023

Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome.

Chun-Liang Lin, Ching-Chan Lin, Tzu-Ting Chen, Wen-Jyi Lo, Shu-Ling Tzeng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chun-Liang LinInstitute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0002-6129-0828
Ching-Chan LinDepartment of Hematology and Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Tzu-Ting ChenDepartment of Hematology and Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Wen-Jyi LoDepartment of Hematology and Oncology, China Medical University Hospital, Taichung 404332, Taiwan.
Shu-Ling TzengInstitute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0002-6312-4161
China Medical University · TWChung Shan Medical University · TW

Funding

China Medical Univer-sity [DMR-108-BC-6]China Medical University [DMR-110-019].National Health Research Institutes [NHRI-180A1-CACO-13191902]
6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) immunity plays an important role in the proliferation and apoptosis of aberrant cells. Immune dysregulation has been studied in various prognostic subgroups. This study analyzed 60 patients with MDS via multidimensional flow cytometry to evaluate the expression of aberrant markers, such as CD7 and cytoplasmic CD3 on lymphocytes. The Revised International Prognostic Scoring System (IPSS-R) scores were used to classify the patients into risk groups. The results showed a significant downregulation of CyCD3- T cells in low-intermediate versus high-risk patients (

Indexed as

apoptosislymphocytesmyelodysplastic syndromeT cells

Identifiers

PMID36648883
PMCPMC9844488
OpenAlexW4315780692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.